Ayumi Sugiura, Satoru Joshita, Yuki Yamashita, Tomoo Yamazaki, Naoyuki Fujimori, Takefumi Kimura, Akihiro Matsumoto, Shuichi Wada, Hiromitsu Mori, Soichiro Shibata, Kaname Yoshizawa, Susumu Morita, Kiyoshi Furuta, Atsushi Kamijo, Akihiro Iijima, Satoko Kako, Atsushi Maruyama, Masakazu Kobayashi, Michiharu Komatsu, Makiko Matsumura, Chiharu Miyabayashi, Tetsuya Ichijo, Aki Takeuchi, Yuriko Koike, Yukio Gibo, Toshihisa Tsukadaira, Hiroyuki Inada, Yoshiyuki Nakano, Seiichi Usuda, Kendo Kiyosawa, Eiji Tanaka, Takeji Umemura
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1+2/3, respectively...
April 3, 2020: Biomedicines